Evidence map›Paper›PMID 32898926›Full record

ArticleNeuropathology and applied neurobiology2021

A simple novel approach for detecting blood-brain barrier permeability using GPCR internalization.

Z Csaba, T Vitalis, C Charriaut-Marlangue, I Margaill, B Coqueran, P-L Leger, I Parente, A Jacquens, L Titomanlio, C Constans and 12 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropathology and applied neurobiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 2 countries.

Z CsabaNeuroDiderot, Inserm U1141, Université de Paris, Paris, France.
T VitalisNeuroDiderot, Inserm U1141, Université de Paris, Paris, France.
C Charriaut-MarlangueNeuroDiderot, Inserm U1141, Université de Paris, Paris, France.
I MargaillResearch Team "Pharmacology of Cerebral Circulation" EA4475, Faculté de Pharmacie de Paris, Université de Paris, Paris, France.
B CoqueranResearch Team "Pharmacology of Cerebral Circulation" EA4475, Faculté de Pharmacie de Paris, Université de Paris, Paris, France.
P-L LegerNeuroDiderot, Inserm U1141, Université de Paris, Paris, France.
I ParenteNeuroDiderot, Inserm U1141, Université de Paris, Paris, France.
A JacquensNeuroDiderot, Inserm U1141, Université de Paris, Paris, France.
L TitomanlioNeuroDiderot, Inserm U1141, Université de Paris, Paris, France.
C ConstansInstitut Langevin, ESPCI Paris, PSL Research University, CNRS UMR7587, Inserm U979, Inserm Technology Research Accelerator in Biomedical Ultrasound, Université de Paris, Paris, France.
C DemeneInstitut Langevin, ESPCI Paris, PSL Research University, CNRS UMR7587, Inserm U979, Inserm Technology Research Accelerator in Biomedical Ultrasound, Université de Paris, Paris, France.
M D SantinBrain and Spine Institute-ICM, Center for NeuroImaging Research - CENIR, Sorbonne Paris Cité, UPMC Université Paris 06, Inserm U1127, CNRS UMR 7225, Paris, France.
S LehericyBrain and Spine Institute-ICM, Center for NeuroImaging Research - CENIR, Sorbonne Paris Cité, UPMC Université Paris 06, Inserm U1127, CNRS UMR 7225, Paris, France.
N PerrièreBrainPlotting, Brain and Spine Institute-ICM, Paris, France.
F GlacialBrainPlotting, Brain and Spine Institute-ICM, Paris, France.
S AuvinNeuroDiderot, Inserm U1141, Université de Paris, Paris, France.
M TanterInstitut Langevin, ESPCI Paris, PSL Research University, CNRS UMR7587, Inserm U979, Inserm Technology Research Accelerator in Biomedical Ultrasound, Université de Paris, Paris, France.
J-F Ghersi-EgeaFluid Team, Lyon Neurosciences Research Center, Inserm U1028, CNRS, UMR5292, University Lyon-1, Villeurbanne, France.
H Adle-BiassetteNeuroDiderot, Inserm U1141, Université de Paris, Paris, France.
J-F AubryInstitut Langevin, ESPCI Paris, PSL Research University, CNRS UMR7587, Inserm U979, Inserm Technology Research Accelerator in Biomedical Ultrasound, Université de Paris, Paris, France.
P GressensNeuroDiderot, Inserm U1141, Université de Paris, Paris, France.
P DournaudNeuroDiderot, Inserm U1141, Université de Paris, Paris, France.ORCID 0000-0002-5553-8946
Inserm · FRCentre National de la Recherche Scientifique · FRAllen Institute for Brain Science · USUniversité Paris Cité · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsImpairment of blood-brain barrier (BBB) is involved in numerous neurological diseases from developmental to aging stages. Reliable imaging of increased BBB permeability is therefore crucial for basic research and preclinical studies. Today, the analysis of extravasation of exogenous dyes is the principal method to study BBB leakage. However, these procedures are challenging to apply in pups and embryos and may appear difficult to interpret. Here we introduce a novel approach based on agonist-induced internalization of a neuronal G protein-coupled receptor widely distributed in the mammalian brain, the somatostatin receptor type 2 (SST2).

methodsThe clinically approved SST2 agonist octreotide (1 kDa), when injected intraperitoneally does not cross an intact BBB. At sites of BBB permeability, however, OCT extravasates and induces SST2 internalization from the neuronal membrane into perinuclear compartments. This allows an unambiguous localization of increased BBB permeability by classical immunohistochemical procedures using specific antibodies against the receptor.

resultsWe first validated our approach in sensory circumventricular organs which display permissive vascular permeability. Through SST2 internalization, we next monitored BBB opening induced by magnetic resonance imaging-guided focused ultrasound in murine cerebral cortex. Finally, we proved that after intraperitoneal agonist injection in pregnant mice, SST2 receptor internalization permits analysis of BBB integrity in embryos during brain development.

conclusionsThis approach provides an alternative and simple manner to assess BBB dysfunction and development in different physiological and pathological conditions.

Indexed as

Capillary PermeabilityAnimalsAntibodies, MonoclonalBlood-Brain BarrierImmunohistochemistryMiceMice, Inbred C57BLOctreotideRatsRats, WistarReceptors, SomatostatinAntibodies, MonoclonalOctreotideReceptors, Somatostatinblood-brain barriercerebral cortexmagnetic resonance imaging (MRI)-guided focused ultrasoundneurodevelopmentneurological diseasesneurovascular unitstroketraumatic brain injury

Identifiers

PMID32898926
PMCPMC7891648
OpenAlexW3086305587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.